Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939731 · ClinicalTrials.gov registry record · Phase 1
Relative Drug Exposures Of Two Formulations of PF-02341066
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00939731 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT00939731, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over, single-dose study employing administration of two PF-02341066 formulations in the fasted state to healthy adult volunteers.
Interventions
- DRUG PF-02341066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939731
The ClinicalTrials.gov registry entry for NCT00939731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-02341066 is the first listed.
NCT00939731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939731 about?
NCT00939731 is a clinical study titled "Relative Drug Exposures Of Two Formulations of PF-02341066". The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over, single-dose study employing administration of two PF-02341066 formulations in the fasted state to healthy adult volunteers.
What is the current status of trial NCT00939731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00939731?
The interventions under investigation include: PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00939731?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.